Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial
Authors' conclusion
Vitamin D supplementation might reduce the incidence of major cardiovascular events, although the absolute risk difference was small and the confidence interval was consistent with a null finding.
Study context
- Population
- Adults aged 60–84 years, Australia, 2014–202021,302 analysed
- Participants
- 21,315 adults
- Comparison
- Monthly vitamin D3 vs placebo
- Vitamin Dn = 10,662
- Placebon = 10,653reference
- Primary endpoint
- Major CV event:
- MI
- Stroke
- Coronary revascularisation
Methodological detailsdouble-blind, placebo-controlled, Median intervention period 5 years; 16 882 completed intervention (placebo 8270 (77.6%); vitamin D 8552 (80.2%))
- Double-blind
- Placebo-controlled
- Median intervention period 5 years; 16 882 completed intervention (placebo 8270 (77.6%); vitamin D 8552 (80.2%))
Primary result
As reported in the abstract
Vitamin D vs PlaceboHazard ratio (95% CI)
Vitamin D
0.91(0.81–1.01)
Vitamin D vs PlaceboDifference in standardised cause specific cumulative incidence at five years, events per 1000 participants (95% CI)
NNT 172
−5.8(−12.2 to 0.5)
Secondary outcomes
| Outcome | HR | |
|---|---|---|
| Major CV event, taking CV drugs at baseline (subgroup) | 0.84 (CI 0.74–0.97) | |
| MI | 0.81 (95% CI 0.67–0.98) | |
| Coronary revascularisation | 0.89 (CI 0.78–1.01) | |
| Stroke | 0.99 (CI 0.80–1.23) | |
| 0.512Hazard ratio (log scale) |
- Major CV event, taking CV drugs at baseline (subgroup): P for interaction=0.12
Original publication
Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →